1. Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols 
Mette Toftager, M.D., Ph.D., Randi Sylvest, M.Sc., Lone Schmidt, M.D., Ph.D., D.M.Sc., Jeanette Bogstad, M.D., Kristine Løssl, M.D., Ph.D., Lisbeth Prætorius, M.D., Anne Zedeler, Ph.D., Thue Bryndorf, M.D., D.M.Sc., Anja Pinborg, M.D., D.M.Sc. 
Fertility and Sterility 
Volume 109, Issue 1, Pages (January 2018)
DOI: /j.fertnstert
Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
An overview of all subjects who started gonadotrophin stimulation in their first assisted reproductive technology cycle after randomization to either short gonadotropin-releasing hormone (GnRH) antagonist or long GnRH agonist protocol. The questionnaire on self-reported physical health was completed four times at: baseline (visit 0), at the day of oocyte retrieval (visit 1), 3 days after embryo transfer (visit 2), and the day of the pregnancy test days after embryo transfer (visit 3). The quality of life questionnaire was completed at visit 3, but before the human chorionic gonadotropin result was known. If the woman did not have an embryo transfer, the questionnaire was completed at visit 2.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions